Acofarma grows in 2023 and proposes a new business model

The Terrassa-based company presented its accounts for the year 2023 at its shareholders' meeting

21 of June of 2024
Acofarma

Acofarma surpasses the 35 million net turnover barrier in 2023. The pharmaceutical company held its Members' Meeting to present the figures for the 2023 financial year. In the last year, according to the data presented by Acofarma, 93% of pharmacies marketed at least one of the products in the Acofarma brand portfolio and it has managed to position itself as the tenth laboratory in unit sales in Spain, as indicated by the HMR consultancy firm. Acofarma has managed to position its compact make-up with sun protection as the best-selling product in Spain. 

At this meeting with its partners, the company presented the new Cosmetics by Acofarma product line, which was created with the aim of introducing a new exclusive line of high quality ingredients for the production and development of cosmetic, pharmaceutical, dermo-aesthetic and medical-aesthetic products. 

Xavier Casas, President of Acofarma, pointed out that "last year we began to lay the foundations needed to set up a new project". This new project had a clear objective: to facilitate the work of its partner pharmaceutical cooperatives (Fedefarma, Grupo Bidafarma and Grupo Unnefar) to promote actions that would provide market vision, actions to promote turnover and the management of centralised services that add value.

Acofarma has implemented and improved new services such as access to continuous training, technical and logistical support or marketing tools that allow pharmacies to enhance their capacity, for example, to offer a better patient care experience and stand out in a highly competitive market. "The redefinition of the business model is focused on increasing the competitiveness of both the cooperatives and the brand," explained the President of Acofarma. Acofarma's aim is to provide a better service to pharmacies. 

Francesc Balletbó, for his part, explained that "from a strategic point of view, we must be able to consolidate these changes. So, it will once again be a year of challenges, but also of many opportunities to continue to grow and prepare for the future without forgetting our raison d'être".

In terms of its distribution model, Acofarma remains committed to the Spanish pharmaceutical distribution model, maintaining and promoting the link with the cooperative and offering value-added solutions.